The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Currently, trastuzumab is one of the key drugs in the treatment strategy for HER2-positive breast cancer. Although metastatic breast cancer is unlikely to be cured, some HER2-positive patients have survived for a long time with complete response to trastuzumab therapy. In HER2-positive metastatic breast cancer, single agent trastuzumab is effective and less toxic. Combination of trastuzumab with cytotoxic drugs is also effective. Therefore, major guidelines recommend using trastuzumab as a key drug in the management of HER2-positive metastatic breast cancer. However, many clinical questions still need to be solved. In this article, recent evidence was reviewed to find some answers about these issues.
- Ohta, M, Tokuda, Y, Suzuki, Y, Kubota, M, Watanabe, T, Fujii, H, Sasaki, Y, Niwa, T, Makuuchi, H, Tajima, T (2001) A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody. Jpn J Clin Oncol 31: pp. 553-556 CrossRef
- National Comprehensive Cancer Network (NCCN). http://www.nccn.org/professionals/physician_gls/default.asp.
- Pietras, RJ, Arboleda, J, Reese, DM, Wongvipat, N, Pegram, MD, Ramos, L, Gorman, CM, Parker, MG, Sliwkowski, MX, Slamon, DJ (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: pp. 2435-2446
- Carlomagno, C, Perrone, F, Gallo, C, Laurentiis, M, Lauria, R, Morabito, A, Pettinato, G, Panico, L, D’Antonio, A, Bianco, AR, Placido, S (1996) c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14: pp. 2702-2708
- Mackey JR, Kaufman B, Clemens M, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Jones A. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2006; abstract 3.
- Nakagami K, Inoue K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Ohashi Y, Sano M, Noguchi S. Randomized Phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2008; abstract 3132.
- Pegram, M, Hsu, S, Lewis, G (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: pp. 2241-2251 CrossRef
- Slamon, DJ, Leyland-Jones, B, Shak, S, Fuchs, H, Paton, V, Bajamonde, A, Fleming, T, Eiermann, W, Wolter, J, Pegram, M, Baselga, J, Norton, L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: pp. 783-792 CrossRef
- Buzdar, AU, Ibrahim, NK, Francis, D, Booser, DJ, Thomas, ES, Theriault, RL, Pusztai, L, Green, MC, Arun, BK, Giordano, SH, Cristofanilli, M, Frye, DK, Smith, TL, Hunt, KK, Singletary, SE, Sahin, AA, Ewer, MS, Buchholz, TA, Berry, D, Hortobagyi, GN (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: pp. 3676-3685 CrossRef
- Untch, M, Eidtmann, H, du Bois, A, Meerpohl, HG, Thomssen, CH, Ebert, A, Harbeck, N, Jackisch, C, Heilman, V, Emons, G, Wallwiener, D, Wiese, W, Blohmer, JU, Hőffken, K, Kuhn, W, Reichardt, P, Muscholl, M, Pauschinger, M, Langer, B, Lűck, HJ (2004) Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur J Cancer 40: pp. 988-997 CrossRef
- Theodoulou, M, Campos, SM, Batist, G, Winer, E, Norton, L, Hudis, C, Welles, L (2002) TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol 21: pp. 55a
- Cortes, J, Dicosimo, S, Climent, MA, Cortés-Funes, H, Lluch, A, Gascón, P, Mayordomo, JI, Gil, M, Benavides, M, Cirera, L, Ojeda, B, Rodríguez, CA, Trigo, JM, Vazquez, J, Regueiro, P, Dorado, JF, Baselga, J (2009) Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II Study. Clin Cancer Res 15: pp. 307-314 CrossRef
- Suzuki, T, Minamide, S, Iwasaki, T, Yamamoto, H, Kanda, H (1997) Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs 15: pp. 219-225 CrossRef
- Tokuda Y, Umemura S, Saito Y, Suzuki Y. Enhanced anti-tumor effect of trastuzumab combined with less cardiotoxic anthracycline, amrubicin, in HER2 positive human cancer xenografts in athymic mice. J Clin Oncol. 2008;26:abstract 14641.
- Marty, M, Cognetti, F, Maraninchi, D, Snyder, R, Mauriac, L, Tubiana-Hulin, M, Chan, S, Gries, D, Anton, A, Lluch, A, Kennedy, J, O’Byrne, K, Conte, P, Green, M, Ward, C, Mayne, K, Extra, JM (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: pp. 4265-4274 CrossRef
- Bontenbal, M, Seynaeve, C, Stouthard, J, Bos, M, Braun, H, Erdkamp, FL, Deijk, G, Schmitz, P, Stelt-Frissen, I, Hamberg, P, Klijn, J (2008) Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in Her2-neu positive, metastatic breast cancer (HERTAX study). J Clin Oncol 26: pp. 44s CrossRef
- Hayes D. Systemic therapy for HER2-positive metastatic breast cancer. UpToDate version 16.3.
- Burstein, HJ, Keshaviah, A, Baron, A, Hart, R, Lambert-Falls, R, Marcom, PK, Gelman, R, Winer, EP (2006) Trastuzumab and vinorelbine or taxane chemotherapy for HER2 + metastatic breast cancer: the TRAVIOTA study. J Clin Oncol 24: pp. 18s CrossRef
- Fujimoto-Ouchi K, Sekiguchi F, Mori K. Preclinical study of continuous administration of trastuzumab as combination therapy after disease progression with trastuzumab monotherapy. Proc Amer Assoc Cancer Res. 2005;46:abstract 5062.
- Minckwitz, G, Zielinski, C, Maarteense, E, Vogel, P, Schmidt, M, Eidtmann, H, Cufer, T, Jongh, FE, Kaufmann, M, Loibl, S (2008) Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05). J Clin Oncol 26: pp. 47s
- O’Shaughnessy, J, Blackwell, KL, Burstein, H, Storniolo, AM, Sledge, G, Baselga, J, Koehler, M, Laabs, S, Florance, A, Roychowdhury, D (2008) A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2 + metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 26: pp. 44s CrossRef
- Tokuda, Y, Ohnishi, Y, Shimamura, K, Iwasawa, M, Yoshimura, M, Ueyama, Y, Tamaoki, N, Tajima, T, Mitomi, T (1996) In vitro and in vivo anti-tumor effects of a humanized monoclonal antibody against c-erbB-2 product. Br J Cancer 73: pp. 1362-1365
- The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review
Volume 16, Issue 4 , pp 295-300
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Metastatic breast cancer
- Industry Sectors
- Author Affiliations
- 1. Department of Breast and Endocrine Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan
- 2. Department of Pathology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan